Intriguingly, there was a trend towards increased deletion in the spleen and a highly significant (approximately five-fold) augmentation of B-cell depletion in the lymph node with rituximab hIgG1 μtp C575S.
← all excerpts
On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation.
1
—
—